Viridian Therapeutics(US:VRDN) Seeking Alphaยท2025-06-09 22:18Group 1 - The discussion in the biotech community has focused on profitable buy-write or covered call strategies for selected biotech stocks over recent months [1] - Viridian Therapeutics, Inc. (NASDAQ: VRDN) has been highlighted as a promising clinical-stage biotech company, despite a significant stock price drop of one-third since the last analysis [2] - The investing group, The Biotech Forum, offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly market commentary [2] Group 2 - The article emphasizes that the analyst holds a beneficial long position in VRDN shares through various financial instruments [3] - There is a disclaimer regarding past performance not guaranteeing future results, and no specific investment advice is provided [4]